PDS Biotechnology (PDSB) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Unicycive Therapeutics (UNCY) over the past year, gaining 3.0% versus a loss of 38.0%. Over five years, UNCY leads with a -88.5% price change compared with -92.5% for PDSB. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $95.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDSB | UNCY |
|---|---|---|
| Share price | $0.7774 | $3.35 |
| Market cap | $95.39M | $97.77M |
| 1-day change | -3.70% | -5.10% |
| YTD return | +0.96% | -41.94% |
| 1-year return | +2.97% | -37.96% |
| 5-year return | -92.46% | -88.53% |
| Forward P/E | — | 4.86 |
| EPS (TTM) | $-0.54 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-34.50M | $-26.55M |
| 52-week high | $1.79 | $8.74 |
| 52-week low | $0.195 | $3.33 |
| Distance from 52-week high | -56.57% | -61.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +478.85% | +685.07% |
| Average volume | 25.64M | 963.80K |
| Shares outstanding | 122.70M | 29.18M |
| Employees | 21 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed UNCY by 40.9 percentage points over the past year.
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
PDSB vs UNCY FAQ
Which is bigger, PDS Biotechnology or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $95.39M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, PDSB or UNCY?
PDSB returned +2.97% over the past 12 months, compared with -37.96% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are PDS Biotechnology and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.